SCHEMBL3556550

SCHEMBL3556550

O=C(O)c1ccc2[nH]c(-c3cccc4c3-c3ccccc3/C4=N/O)nc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.50
RAB9A P51151 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
ALDH1A1 P00352 2/20 0.50
HPGD P15428 2/20 0.50
NPC1 O15118 2/20 0.50
KMT2A Q03164 3/20 0.46
POLB P06746 2/20 0.43
MAPT P10636 2/20 0.43
TP53 P04637 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CHEK2 O96017 2/20 0.43
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
MEN1 O00255 2/20 0.42
NR4A2 P43354 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3556552 1.00 KDM4E (0.50) KDM4ERAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL3556548 1.00 KDM4E (0.50) KDM4ERAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL2309903 0.85 RAB9A (0.50) KDM4ERAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL2310791 0.83 NPC1 (0.46) KDM4ERAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL2310794 0.83 NPC1 (0.46) KDM4ERAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL2309658 0.83 RAB9A (0.55) KDM4ERAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL2309662 0.83 RAB9A (0.55) KDM4ERAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL12431585 0.83 RAB9A (0.55) KDM4ERAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL3550808 0.80 KDM4E (0.45) KDM4ERAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL2316176 0.80 SCD (0.47) KDM4ERAB9ASMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674795-B2 Fluorene derivatives, composition containing said derivatives and the use thereof AVENTIS PHARMA SA (FR) 2010-03-09 US disclosed
US-20080153837-A1 Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof AVENTIS PHARMA S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153837-A1 Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof HSP90B1, HSP90AB1, HSP90AA1 KDM4E 3419/4885RAB9A 1012/4885SMN1; SMN2 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.